DFE Pharma launches MCC - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

DFE Pharma launches MCC


As of February 2013 DFE Pharma offers two grades of Microcrystalline Cellulose (MCC) - Pharmacel® 101 and Pharmacel® 102 - to its global customers. MCC is, together with lactose and superdisintegrants, one of the most commonly used diluents in drug formulations. These three key excipients are now available from one single supplier DFE Pharma, unlocking potential synergies for you.

In December 2011, DFE Pharma completed the acquisition of Brahmar Cellulose Products Private Limited (BCPL), one of India’s leading excipient producers. After a successful period of consolidation, BCPL is now a fully integrated part of the global DFE Pharma organisation. We believe this gives us additional capability to serve our customers even better than before. The BCPL acquisition allowed DFE Pharma to significantly broaden its excipients portfolio with world-class MCC products.

The MCC global market introduction is an exciting move that enables us to build on a combination of strengths, further widening our portfolio and taking an important step in our pursuit of excipient excellence. All our capabilities, quality standards and support services apply as much to MCC as to our other products. We continue to develop and produce the best possible excipient solutions for our customers and look forward to serving you in the future with reliable solutions in pharmaceutical excipients.

DFE Pharma

www.dfepharma.com

pharma@dfepharma.com

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here